|
|
Vaccine Detail
|
ESR1 peptide vaccine |
| Vaccine Information |
- Vaccine Name: ESR1 peptide vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: ESR1 (NCT04270149; NCIT_C175590)
- Immunization Route: subcutaneous injection
- Description: This is a vaccine comprised of estrogen receptor alpha (ERa; estrogen receptor 1; ESR1) mutant peptides, combined with the immunoadjuvants granulocyte-macrophage colony-stimulating factor (GM-CSF) and montanide ISA, with potential immunomodulating and antineoplastic activities. ESR1 mutant peptides in the ESR1 peptides/GM-CSF/montanide ISA vaccine may activate the immune system to induce an immune response against tumor cells expressing these ESR1 mutations. (NCIT_C175590) Cancer peptides used in this vaccine are derived from the estrogen receptor and are combined with the adjuvant Montanide ISA and GM-CSF to enhance their immune response. The vaccine may improve outcomes of patients with endocrine resistant breast cancer. (NCT04270149)
|
| Host Response |
|
|
| References |
NCIT_C175590: ESR1 Peptides/GM-CSF/Montanide ISA Vaccine [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C175590]
NCT04270149: Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer [https://clinicaltrials.gov/study/NCT04270149]
|
|
